OBJECTIVE To examine, among patients with type 2 diabetes, the association between
hospitalization for heart failure (hHF) and treatment with dipeptidyl peptidase 4 inhibitors …

OBJECTIVE This 24-week trial assessed the efficacy and safety of saxagliptin as add-on
therapy in patients with type 2 diabetes with inadequate glycemic control with metformin …

Type 2 diabetes mellitus (T2DM) is a global epidemic with increasing impact on individuals
and healthcare providers. Available treatments (such as metformin, sulfonylureas …

Abstract Background and Objective Patients with type 2 diabetes mellitus often have
impaired renal function or may have impaired hepatic function, which can pose significant …

Background Data are lacking on the long-term effect on cardiovascular events of adding
sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes …

The objectives of the studies were to assess the safety, tolerability and the pharmacokinetic
(PK) and pharmacodynamic (PD) properties following 2 weeks of oral once-daily (QD) doses …

Aim To compare the long‐term safety, tolerability and efficacy of saxagliptin vs. glipizide as
add‐on therapy to metformin. Methods Adults with glycated haemoglobin (HbA1c)> 6.5 …

Background Dipeptidyl peptidase‐4 inhibitors improve glycaemic control in patients with
type 2 diabetes mellitus when used as monotherapy or in combination with other anti …

This article has been corrected. The original version (PDF) is appended to this article as a
Supplement. Background: Recent postmarketing trials produced conflicting results about the …

Aims: Assess the efficacy and safety of saxagliptin added to a submaximal sulphonylurea
dose vs. uptitration of sulphonylurea monotherapy in patients with type 2 diabetes and …